Sponsor: Merck Sharp & Dohme Corp.
Protocol MK-7339-007: A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer.
Eligible patients will have a mutation in any one of the following genes: BRCA1, BRCA2; or a loss of heterozygosity score of ≥16
For more information please contact the clinical research department: 631-675-5075